- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02542371
Use of 99mTc Tilmanocept for Imaging Arterial Inflammation
Aperçu de l'étude
Description détaillée
Detailed Description:
Patients with HIV have been shown to have increased atherosclerotic risk compared to age-matched controls, and this risk is thought to be related to increased systemic immune activation. Specifically, systemic immune activation may contribute to destabilizing coronary atherosclerotic plaque, leading to plaque rupture and myocardial infarction. This study is intended to measure arterial uptake of the macrophage specific marker 99mTc-Tilmanocept using single photon emission computed tomography, applied initially to a group of HIV-infected patients with known subclinical coronary atherosclerosis on CCTA. Moreover, traditional markers of CVD risk and inflammatory markers will be assessed in relation to CV imaging outcomes. Positive findings in the index HIV group with known subclinical atherosclerosis will prompt subsequent study of three comparison groups, as above.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
HIV infected subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- known active opportunistic infection requiring ongoing medical therapy (not including Hepatitis B/C)
- CD4 count < 50 cells/mm3
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV infected subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of clean aorta/ coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV infected subjects with known subclinical atherosclerosis
HIV negative subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV negative subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of clean aorta/coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV negative subjects with known subclinical atherosclerosis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cas-témoins
- Perspectives temporelles: Transversale
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
HIV infected with known subclinical atherosclerosis
|
|
|
HIV infected without known subclinical atherosclerosis
|
|
|
Non-HIV infected with known subclinical atherosclerosis
|
|
|
Non-HIV infected without known subclinical atherosclerosis
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients
Délai: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Aortic plaque burden and morphology on CCTA in HIV Patients
Délai: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Traditional markers of cardiovascular disease (CVD) risk and inflammatory markers in relation to cardiovascular imaging outcomes
Délai: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Imaging assessments in the coronary vasculature in HIV patients
Délai: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Comparison of imaging assessments b/ HIV patients w/ known subclinical atherosclerosis, HIV patients w/o known subclinical atherosclerosis, non HIV patients w/ known subclinical atherosclerosis and non HIV patients w/o known subclinical atherosclerosis
Délai: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
99mTc-Tilmanocept uptake on SPECT/CT in regions other than the aorta
Délai: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Steven Grinspoon, M.D., Massachusetts General Hospital
Publications et liens utiles
Publications générales
- Toribio M, Wilks MQ, Hedgire S, Lu MT, Cetlin M, Wang M, Alhallak I, Durbin CG, White KS, Wallis Z, Schnittman SR, Stanley TL, El-Fakhri G, Lee H, Autissier P, Zanni MV, Williams KC, Grinspoon SK. Increased Macrophage-Specific Arterial Infiltration Relates to Noncalcified Plaque and Systemic Immune Activation in People With Human Immunodeficiency Virus. J Infect Dis. 2022 Nov 11;226(10):1823-1833. doi: 10.1093/infdis/jiac301.
- Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, Autissier P, Foldyna B, Stone L, Martin A, Cope F, Abbruzzese B, Brady T, Hoffmann U, Williams KC, El-Fakhri G, Grinspoon SK. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 Apr 15;215(8):1264-1269. doi: 10.1093/infdis/jix095.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2014P001832
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .